Tenderwize
Retour à la recherche

Framework contracts for innovative infectious disease therapeutics

Health and Digital Executive Agency (HaDEA)·Brussels, Belgium·EUR 252M·Deadline Sep 02, 2026 · 7 days left·Neg W Call·Services·Framework
Inscrivez-vous pour sauvegarderOpen documents
High value
Titre original de l'avis

Belgium – Research and development services and related consultancy services – Multiple sourcing Framework Contracts to speed up the development of and access to innovative medical countermeasures Next Generation Therapeutics for Infectious Diseases

75/100

Score d'opportunité

PromisingHigh complexity
ServicesFrameworkOpen
Pourquoi ce score ?

Opportunité

75 / 100

Complexité

85 / 100

Facteurs de risque

Highly innovative and specialized therapeutic areas (e.g., host-targeted, broad-spectrum) may require cutting-edge R&D...

Procurement documents are not analyzed; detailed requirements, terms, and conditions may impose unforeseen obligations.

Submission deadline in 7 days

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • EUR 252M estimated value
  • Framework procurement
  • Services contract
  • 2 lots
  • Lot 1: Development of pathogen-targeted scalable therapeutics, innovative combination therapies, and alternative IV route products for viral infections, ARDS, or sepsis.
  • Lot 2: Development of host-targeted scalable therapeutics, innovative combination therapies, and alternative IV route products for viral infections, ARDS, or sepsis.
Afficher le résumé complet

This Pre-Commercial Procurement (PCP) call, led by the Health and Digital Executive Agency (HaDEA), aims to accelerate the development of innovative medical countermeasures for infectious diseases, specifically next-generation therapeutics. The tender consists of two lots: 'Highly Innovative Therapeutics' (Lot 1, value €138M) focusing on pathogen-targeted scalable therapeutics, and 'Advanced Therapeutics' (Lot 2, value €114M) focusing on host-targeted scalable therapeutics. Both lots include combination therapies and alternative IV routes. The overall estimated value is €252M, funded under EU4Health. The procedure is a negotiated procedure with call for competition, resulting in multiple sourcing framework contracts. Evaluation is 80% quality and 20% price. Submission deadline: 2026-09-02.

Risques

Highly innovative and specialized therapeutic areas (e.g., host-targeted, broad-spectrum) may require cutting-edge R&D...

Procurement documents are not analyzed; detailed requirements, terms, and conditions may impose unforeseen obligations.

Submission deadline in 7 days

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must address viral infections, ARDS, or sepsis resulting from infections.
  • Pathogen-targeted therapeutics (Lot 1) or host-targeted therapeutics (Lot 2).
  • Excludes small molecules, monoclonal antibodies; includes direct/indirect antivirals, immune modulators.

Critères d'attribution

Lot 1

Quality criterion with weight 80% (per-exa). — 80%Price criterion with weight 20% (per-exa). — 20%

Lot 2

Quality criterion with weight 80% (per-exa). — 80%Price criterion with weight 20% (per-exa). — 20%

Acheteur

Localisation

Brussels, BEL

Identifiant

HADEA

Activité

General public services

Lots (2)

LOT-0001

Highly Innovative Therapeutics

Lot 1 targets pathogen-targeted scalable therapeutics, innovative combination therapies, and therapeutics designed for alternative routes to IV administration.

ServicesFrameworkEU fundedElectronic submission

EUR 252M

Valeur estimée

Durée

108 MONTH

Catégorie

Research

Critères d'attribution

Best price-quality ratio

Date limite

Deadline Sep 02, 2026

LOT-0002

Advanced Therapeutics

Lot 2 targets host-targeted scalable therapeutics, innovative combination therapies, and therapeutics designed for alternative routes to IV administration.

ServicesFrameworkEU fundedElectronic submission

EUR 252M

Valeur estimée

Durée

69 MONTH

Catégorie

Research

Critères d'attribution

Best price-quality ratio

Date limite

Deadline Sep 02, 2026

Détails de la procédure

Date de publication
01 Jul 2026
Langues
English, Bulgarian

Métadonnées de référence

Base juridique
32024R2509

Identifiants de référence

ID de l'appel d'offres
456593-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Spain – Research and experimental development services – Pre-commercial Procurement of an innovative Systemic Sustainability Transition Solution for Health Care Organisations (suHCO)

Oct 9

Belgium – Research and experimental development services – Long-term API stockpiling and rapid finished dose form manufacture

Sep 21

Norway – Research and development services and related consultancy services – Preventive conversations as a means of the police ́s preventive work.

Sep 8

Germany – Research and experimental development services – Toolkit für aktives Verteilnetzmanagement

Aug 31

Norway – Research and development services and related consultancy services – Evaluation of the police's national efforts against criminal networks.

Sep 10

Spain – Accounting, auditing and fiscal services – SDA servicios profesionales especializados

Jun 2